Clinical Trial Update: Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports on the tolerability and potential efficacy of AD17002 in subjects with allergic rhinitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AD17002

Snippet

Sponsor: Advagene Biopharma Co. Ltd. | Conditions: Allergic Rhinitis | Phase 1, Phase 2 | Status: COMPLETED